Peter Attia· MD
now if you still have options that you can lower it further yeah the trials show yeah there is incremental reduction events but it's a much smaller absolute risk reduction and dropping at the 50 percent or so
Loading…
The evidence is convergent. Multiple independent sources reach the same conclusion, the underlying mechanism is well-characterized, and even the field's most cautious voices treat it as worth doing.
now if you still have options that you can lower it further yeah the trials show yeah there is incremental reduction events but it's a much smaller absolute risk reduction and dropping at the 50 percent or so
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
Bookmarking — the dossier-vs-overview split is the right call. Most of the time I want overview; sometimes I want receipts.
Would love a "what would change this verdict" RSS feed. Sign me up if it exists.
it just further convinced us to uh hit low it hit on uh april b containing lipoproteins as hard as we can
it's the single most important thing that you can do in the plasma to reduce the risk of atherosclerotic disease
if you look at the kaplan-meier curves they're still going in opposite direction they haven't stabilized so and i talked earlier about the cholesterol treatment trial is curve uh the the data from the fourier and odyssey trial they fall exactly on the same uh curve where you're looking at achieved apob levels and reduction in event
if you plot all the all the clinical trials together if you plot the apob lowering effect to the reduction in cardiovascular disease you can see that all these trials line perfectly on the line
but we do think that there's still merit of course we know there's Merit to raising LDL cholesterol and apob you mean lowering I'm sorry rate lowering perhaps this CTP inhibitor could be part of the armamentarium to do that
most people would agree that non-htl and EPO B are a better prognostic marker and a better measure of therapy than LDL cholesterol by the free DeWalt formula
the data on this is uh as unambiguous as any data are in medicine from clinical trials epidemiologic trials and mandelian randomization in other words you have the only three layers of evidence you can ever look to experimental data Mr and clinical EPI and they all say the same thing there is a log linear reduction in ascvd as apob goes down
but amongst the amongst the variants that decrease LDL and correspondingly decrease apo it is a very very consistent effect and again regardless of the genetic variant, it has the same risk reduction.